INTRODUCTION
Clinical presentation of pulmonary hypoplasia following oligohydramnios may vary from asymptomatic to lethal pulmonary insufficiency. Accurate diagnosis of pulmonary hypoplasia requires either lung biopsy or autopsy and in the absence of a definitive pathologic diagnosis, pulmonary hypoplasia is clinically a diagnosis of exclusion. Despite the lack of reliable diagnostic criteria, the diagnosis of pulmonary hypoplasia can be presumed in certain conditions, including prolonged rupture of membranes (ROM) (see Table 1 ). 1 With improved obstetric care, delivery of infants after prolonged ROM and oligohydramnios is becoming a more common occurrence. Infants born after ROM occurring earlier than 25 weeks' gestation and having severe oligohydramnios ( >14 days) have a mortality rate ranging from 70% to 95%. 2 -7 A recent study suggests that treating these infants with inhaled nitric oxide (iNO) may dramatically improve their survival. 8 The two cases described in this report provide further support for the concept that nitric oxide-sensitive pulmonary hypertension may play a significant role in the disease process for some of these infants.
CASE REPORT #1
The patient was the 1440-g appropriate for gestational age (AGA) male product delivered at 29 4 / 7 weeks' gestation to a 42-year-old gravida 3, para 2, aborta 1 female with unremarkable maternal laboratory findings (group B streptococcal disease (GBS) -negative), but with a complicated pregnancy history. ROM occurred at 22 weeks. The fetus was monitored in the hospital starting at 24 weeks' gestation with serial ultrasounds noting severe oligohydramnios. Three courses of maternal betamethasone were given, and antibiotics were given until 28 weeks' gestation. The infant was delivered by cesarean section due to concerns for chorioamnionitis. Continuous positive airway pressure (CPAP) was provided in the delivery room for an initial heart rate of less than 100. Apgars were 7 at 1 minute and 9 at 5 minutes. The infant was taken to the neonatal intensive care unit (NICU) where he was intubated for respiratory distress and then given surfactant 30 minutes after birth. FiO 2 was weaned from 100% to 70% after surfactant; however, the infant remained on high ventilator settings with a mean airway pressure of 14. He developed refractory hypoxia at about 4 hours of age, with oxygen saturations (SaO 2 ) of 70% to 80%, prompting transition to high-frequency oscillating ventilation (HFOV) with only modest improvement in oxygenation (SaO 2 80% to 90%). Surfactant was repeated 6 hours after birth without improvement in oxygenation. Ventilation remained adequate during this time (PaCO 2 50 to 60). Two hours later his SaO 2 dropped to 40% and remained there for 2 hours despite increasing the mean airway pressure (MAP) to 22, sedation, and aggressive hand-bagging attempts (peak inspiratory pressure (PIP) 32, peak end-expiratory pressure (PEEP) 5, rate 90). A blood gas revealed both metabolic and respiratory acidosis for which he was given normal saline and sodium bicarbonate to which he slowly responded and stabilized. Despite good lung compliance and relatively clear lung fields on chest radiograph, the patient's oxygenation was labile and attempts to wean ventilator settings were unsuccessful. His clinical course was consistent with pulmonary hypertension. His periods of lability were characterized by pre-and postductal saturation differences of about 20%, oxygen indices
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increasing from 6 to 30, whereas ventilation remained adequate (PaCO 2 35 to 50). These episodes responded to alkalinization and sedation. Congenital heart disease was considered unlikely given his normal cardiac anatomy on fetal ultrasounds, his physical exam and his occasional PaO 2 of greater than 150. Due to his repeated episodes of hypoxia and our inability to wean him from high mean airway pressures and 100% oxygen, he was transferred for a trial of iNO. Nitric oxide was started in the transport isolette at 10 ppm (as described in Ref. 8 ) per our compassionate care protocol. Transcutaneous PaO 2 increased from 60 to 550 and his perfusion improved dramatically while moving him from the NICU into the ambulance. Capillary PaO 2 , PaCO 2 , and SaO 2 in the ambulance correlated with the transcutaneous monitor, so both FiO 2 and MAP were decreased. Within 15 minutes, MAP was decreased 30% and FiO 2 weaned from 100% to 50%. Within 4 hours the infant was ventilated well on decreased ventilator support, 5 ppm iNO and 25% FiO 2 with SaO 2 >96%. He was weaned slowly from iNO and extubated on day of life 6. He was discharged home at 36 weeks' gestational age without supplemental oxygen requirements.
CASE REPORT #2
The patient was a 1840-g appropriate for gestational age female infant delivered at 31 weeks' gestation to a 42-year-old gravida 1, para 0 mother with a complicated pregnancy history. ROM occurred at 18 weeks. The fetus was monitored in the hospital starting at 24 weeks' gestation with serial ultrasounds noting severe oligohydramnios. Seven courses of maternal betamethasone were given, and antibiotics were given until 28 weeks' gestation. Onset of labor with breech presentation resulted in delivery by cesarean section. Apgar scores were 6 at 1 minute and 8 at 5 minutes. The infant was taken to the neonatal intensive care unit where she was initially placed in hood oxygen for minimal respiratory distress but required intubation and surfactant for respiratory distress at 8 hours of age. The infant was easily ventilated on low settings (MAP 4 to 6 cm H 2 O), and the FiO 2 was decreased from 100% to 45% after surfactant. She became acutely hypoxic about 12 hours after birth, with SaO 2 of 40% to 50% prompting increased ventilator settings, aggressive hand-bagging and then transition to high-frequency oscillating ventilation with only modest improvement in oxygenation (SaO 2 50% to 60%). Surfactant was repeated twice at 6-hour intervals without improvement in oxygenation. Ventilation and oxygenation were poor (PaCO 2 >90, PaO 2 <30) for approximately 8 hours (oxygen index 45 to 115). Prostaglandin infusion was initiated until an echocardiogram revealed normal cardiac anatomy, and severe pulmonary hypertension with right to left shunting across a patent foramen ovale and ductus arteriosus. The patient was alkalinized with THAM due to her hypercarbia. A trial dose of tolazoline improved her oxygenation but was not tolerated due to severe systemic hypotension, despite pressor support. The infant's respiratory status remained labile with persistent hypoxemia (PaO 2 25 to 42 mm Hg,) despite alkalinization, high ventilator settings, sedation, and pressor support. She was transferred for a trial of iNO. Following iNO, FiO 2 was decreased from 100% to 40% within 48 hours and ventilator settings gradually decreased. iNO was weaned then discontinued after 6 days of therapy as she was stable on a low MAP. Two days later she developed fulminant respiratory failure requiring high ventilator settings, sedation, paralysis, a chest tube for a pneumothorax, steroids, and reinitiation of iNO. She responded to the combination of therapies. She was weaned from iNO over a 3-week period, but remained intubated until 65 days of age. She was treated with CPAP for another month before transitioning to 1 to 2 l/min nasal cannula oxygen. She was discharged at 4 months of life on oxygen, steroids, diuretics and aerosols. At 2 years of life she is alert, interactive, and walking but she remains on oxygen and multiple aerosols. Her growth is poor ( <5th percentile for weight, 10th percentile for length, 40th percentile for head circumference).
DISCUSSION
Pulmonary hypoplasia due to prolonged ROM (PROM) and oligohydramnios presents a serious management challenge to neonatal care providers. The diagnosis of pulmonary insufficiency is often difficult and thus care providers often find themselves responding to, rather than ''staying a step ahead'' of these patients. Premature infants with PROM are also at risk for pneumonia, sepsis, and respiratory distress syndrome. 1, 9 Recent obstetric studies have been useful in identifying a subgroup of neonates with PROM at highest risk for mortality. Neonates with ROM before 25 weeks' gestation and severe oligohydramnios greater than 14 days have a >75% risk of mortality. 2 -7 The timing and severity of oligohydramnios are likely to influence growth and morphogenesis of the developing lung. Lung growth is in the canalicular stage of development until 25 weeks of gestation. Normal transition to the saccular stage of development (where a blood-gas interface forms) requires the production of fluid by the fetal lung. Lung fluid is kept pressurized by the combination of laryngeal closure and fluid production by the respiratory epithelia. The pressure of the fetal lung fluid is important for lung growth as illustrated by the pulmonary hyperplasia seen in neonates with laryngeal agenesis and by the pulmonary hypoplasia seen in neonates with oligohydramnios. 9 -11 Pulmonary hypoplasia, although defined as a decreased lung size, is also accompanied by variable degrees of dysplasia. In autopsy samples from neonates with ROM >14 days, vascular hypoplasia and increased arteriole muscularization were found. 9 Increased arteriolar muscularization, abnormal capillary formation, and thickening of the blood-gas barrier were demonstrated in animal models where stretch-induced lung growth was impaired. Although cellular components of the signal transduction cascade involved in stretch-induced growth and differentiation in the lung remain unclear, regulation of vascular endothelial growth factor (VEGF), and the mitogen-activated protein kinase cascade (MAPK) are known to influence lung morphogenesis. 12 -16 Abnormalities in morphogenesis of both vascular and airway compartments likely contribute to the pulmonary hypertension, 1, 17 ventilation-perfusion (V/Q) mismatch, and alveolar hypoventilation seen in patients with PROM early in gestation.
Both of the patients described in this report and eight patients described in a study by Peliowski et al. 8 had ROM earlier than 25 weeks' gestation and severe oligohydramnios for greater than 14 days, placing them at high mortality risk. In addition, none of the 10 responded to surfactant, also placing them at high mortality risk. 18 All 10 patients responded to iNO, and 6 of the 10 had pulmonary hypertension demonstrated by echocardiography. In patient 2, iNO was effective in treating severe pulmonary hypertension. In patient 1, iNO dramatically improved oxygenation likely relieving pulmonary hypertension or improving severe ventilation-perfusion mismatch. Because both of these infants were at high risk of mortality, we felt it ethical to use iNO as an experimental therapy in spite of the lack of studies in preterm infants.
Although iNO was found a safe and useful therapy for pulmonary hypertension in full term infants, 19 -21 its use in premature infants has not been extensively studied. Based on pilot studies in premature infants with respiratory failure of differing etiology, 8,22 -24 a multicenter, randomized, double-blind, placebo-controlled trial is currently underway to address the use of iNO for preterm infants. Unlike tolazoline, which decreases both pulmonary and systemic vascular resistance, iNO selectively targets pulmonary vascular resistance. Use of iNO in preterm infants may allow for more directed therapy and hopefully minimize ventilator and oxygen-induced lung injury to their immature lungs.
Because preterm infants are at increased risk of intraventricular hemorrhage, periventricular leukomalacia, patent ductus arteriosus, retinopathy of prematurity and impaired neurodevelopmental outcome, a multicenter trial will be critical for documenting the risks and benefits of iNO in premature infants with PROM. It is presently unclear whether the complications of prematurity might be adversely influenced by the use of iNO. It is of theoretical concern that use of iNO may increase the risk of hemorrhage, because iNO inhibits platelet aggregation. It remains unclear whether increased lipid peroxidation and peroxynitrite formation shown in laboratory studies may influence lung injury or repair in vivo. 22 -24 Currently, the use of iNO in premature infants remains experimental and guidelines for its use in compassionate care situations may be developed within institutional review boards. 25 
